Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 194 articles:
HTML format
Text format



Single Articles


    January 2017
  1. MOCCIA M, Palladino R, Lanzillo R, Carotenuto A, et al
    Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.
    PLoS One. 2017;12:e0169489.
    PubMed     Text format     Abstract available


  2. BROCHET B, Deloire MS, Perez P, Loock T, et al
    Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.
    PLoS One. 2017;12:e0168834.
    PubMed     Text format     Abstract available


  3. LIBERTINOVA J, Meluzinova E, Tomek A, Horakova D, et al
    Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNbeta.
    PLoS One. 2017;12:e0169957.
    PubMed     Text format     Abstract available


  4. RAFFEL J, Gafson AR, Dahdaleh S, Malik O, et al
    Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    PLoS One. 2017;12:e0169546.
    PubMed     Text format     Abstract available


  5. KAVALIUNAS A, Manouchehrinia A, Danylaite Karrenbauer V, Gyllensten H, et al
    Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
    PLoS One. 2017;12:e0169460.
    PubMed     Text format     Abstract available


  6. HURTADO-GUERRERO I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, et al
    Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNss in Multiple Sclerosis Patients According to the Therapeutic Response to IFNss.
    PLoS One. 2017;12:e0170031.
    PubMed     Text format     Abstract available


  7. UECKER FC, Olze H, Kunte H, Gerz C, et al
    Longitudinal Testing of Olfactory and Gustatory Function in Patients with Multiple Sclerosis.
    PLoS One. 2017;12:e0170492.
    PubMed     Text format     Abstract available


  8. ZOU L, Wang H, Xiao Z, Fang Q, et al
    Tai chi for health benefits in patients with multiple sclerosis: A systematic review.
    PLoS One. 2017;12:e0170212.
    PubMed     Text format     Abstract available


  9. MOON Y, McGinnis RS, Seagers K, Motl RW, et al
    Monitoring gait in multiple sclerosis with novel wearable motion sensors.
    PLoS One. 2017;12:e0171346.
    PubMed     Text format     Abstract available


  10. LINK J, Ramanujam R, Auer M, Ryner M, et al
    Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
    PLoS One. 2017;12:e0170395.
    PubMed     Text format     Abstract available


  11. MORANDI E, Tanasescu R, Tarlinton RE, Constantinescu CS, et al
    The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0172415.
    PubMed     Text format     Abstract available


  12. BEHBEHANI R, Abu Al-Hassan A, Al-Salahat A, Sriraman D, et al
    Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.
    PLoS One. 2017;12:e0172120.
    PubMed     Text format     Abstract available


  13. FAIZY TD, Thaler C, Ceyrowski T, Broocks G, et al
    Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period.
    PLoS One. 2017;12:e0172923.
    PubMed     Text format     Abstract available


  14. KOMEGAE EN, Souza TA, Grund LZ, Lima C, et al
    Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.
    PLoS One. 2017;12:e0171796.
    PubMed     Text format     Abstract available


  15. WENDEBOURG MJ, Heesen C, Finlayson M, Meyer B, et al
    Patient education for people with multiple sclerosis-associated fatigue: A systematic review.
    PLoS One. 2017;12:e0173025.
    PubMed     Text format     Abstract available


  16. MULS N, Nasr Z, Dang HA, Sindic C, et al
    IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.
    PLoS One. 2017;12:e0173780.
    PubMed     Text format     Abstract available


  17. HEGEN H, Auer M, Bsteh G, Di Pauli F, et al
    Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
    PLoS One. 2017;12:e0174005.
    PubMed     Text format     Abstract available


  18. AYUSO T, Aznar P, Soriano L, Olaskoaga A, et al
    Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis.
    PLoS One. 2017;12:e0174726.
    PubMed     Text format     Abstract available


  19. GIESS RM, Pfuhl C, Behrens JR, Rasche L, et al
    Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis.
    PLoS One. 2017;12:e0175279.
    PubMed     Text format     Abstract available


  20. DOBRAKOWSKI P, Bogocz M, Cholewa K, Rajchel M, et al
    Month of birth and level of insolation as risk factors for multiple sclerosis in Poland.
    PLoS One. 2017;12:e0175156.
    PubMed     Text format     Abstract available


  21. ZHAO Y, Healy BC, Rotstein D, Guttmann CR, et al
    Exploration of machine learning techniques in predicting multiple sclerosis disease course.
    PLoS One. 2017;12:e0174866.
    PubMed     Text format     Abstract available


  22. KRAMER J, Tenberge JG, Kleiter I, Gaissmaier W, et al
    Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    PLoS One. 2017;12:e0174858.
    PubMed     Text format     Abstract available


  23. SHARMA S, Zhang Y
    Fourier transform power spectrum is a potential measure of tissue alignment in standard MRI: A multiple sclerosis study.
    PLoS One. 2017;12:e0175979.
    PubMed     Text format     Abstract available


  24. NAVAS-MADRONAL M, Valero-Mut A, Martinez-Zapata MJ, Simon-Talero MJ, et al
    Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.
    PLoS One. 2017;12:e0175538.
    PubMed     Text format     Abstract available


  25. SCHNEIDER R, Bellenberg B, Hoepner R, Kolb EM, et al
    Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    PLoS One. 2017;12:e0176415.
    PubMed     Text format     Abstract available


  26. INGLESE M, Petracca M, Mormina E, Achiron A, et al
    Cerebellar volume as imaging outcome in progressive multiple sclerosis.
    PLoS One. 2017;12:e0176519.
    PubMed     Text format     Abstract available


  27. IZQUIERDO G, Damas F, Paramo MD, Ruiz-Pena JL, et al
    The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
    PLoS One. 2017;12:e0176174.
    PubMed     Text format     Abstract available


  28. CHARVET LE, Yang J, Shaw MT, Sherman K, et al
    Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial.
    PLoS One. 2017;12:e0177177.
    PubMed     Text format     Abstract available


  29. MOLLISON D, Sellar R, Bastin M, Mollison D, et al
    The clinico-radiological paradox of cognitive function and MRI burden of white matter lesions in people with multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0177727.
    PubMed     Text format     Abstract available


  30. MCGINNIS RS, Mahadevan N, Moon Y, Seagers K, et al
    A machine learning approach for gait speed estimation using skin-mounted wearable sensors: From healthy controls to individuals with multiple sclerosis.
    PLoS One. 2017;12:e0178366.
    PubMed     Text format     Abstract available


  31. PARDO E, Carcamo C, Uribe-San Martin R, Ciampi E, et al
    Galectin-8 as an immunosuppressor in experimental autoimmune encephalomyelitis and a target of human early prognostic antibodies in multiple sclerosis.
    PLoS One. 2017;12:e0177472.
    PubMed     Text format     Abstract available


  32. LANDI D, Albanese M, Buttari F, Monteleone F, et al
    Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
    PLoS One. 2017;12:e0165415.
    PubMed     Text format     Abstract available


  33. RIGHART R, Schmidt P, Dahnke R, Biberacher V, et al
    Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients.
    PLoS One. 2017;12:e0179590.
    PubMed     Text format     Abstract available


  34. BERNITSAS E, Khan O, Razmjou S, Tselis A, et al
    Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis.
    PLoS One. 2017;12:e0181431.
    PubMed     Text format     Abstract available


  35. ITOH Y, Voskuhl RR
    Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
    PLoS One. 2017;12:e0181349.
    PubMed     Text format     Abstract available


  36. BSTEH G, Ehling R, Walchhofer LM, Hegen H, et al
    Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis-The PaSiMS II study.
    PLoS One. 2017;12:e0181458.
    PubMed     Text format     Abstract available


  37. KIM HH, Jeong IH, Hyun JS, Kong BS, et al
    Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance.
    PLoS One. 2017;12:e0181758.
    PubMed     Text format     Abstract available


  38. WURTH S, Kuenz B, Bsteh G, Ehling R, et al
    Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.
    PLoS One. 2017;12:e0182462.
    PubMed     Text format     Abstract available


  39. MESSINA S, Solaro C, Righini I, Bergamaschi R, et al
    Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
    PLoS One. 2017;12:e0180651.
    PubMed     Text format     Abstract available


  40. ABDELHAK A, Hottenrott T, Mayer C, Hintereder G, et al
    CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.
    PLoS One. 2017;12:e0182647.
    PubMed     Text format     Abstract available


  41. THALER C, Schneider T, Sedlacik J, Kutzner D, et al
    T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis.
    PLoS One. 2017;12:e0183099.
    PubMed     Text format     Abstract available


  42. MODICA CM, Schweser F, Sudyn ML, Bertolino N, et al
    Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis.
    PLoS One. 2017;12:e0182729.
    PubMed     Text format     Abstract available


  43. MOROSO A, Ruet A, Lamargue-Hamel D, Munsch F, et al
    Microstructural analyses of the posterior cerebellar lobules in relapsing-onset multiple sclerosis and their implication in cognitive impairment.
    PLoS One. 2017;12:e0182479.
    PubMed     Text format     Abstract available


  44. CEUNINCK VAN CAPELLE A, Meide HV, Vosman FJH, Visser LH, et al
    A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT's) in multiple sclerosis (MS).
    PLoS One. 2017;12:e0182806.
    PubMed     Text format     Abstract available


  45. PUTHENPARAMPIL M, Federle L, Poggiali D, Miante S, et al
    Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis.
    PLoS One. 2017;12:e0183957.
    PubMed     Text format     Abstract available


  46. MASUDA H, Hirano S, Takahashi N, Hatsugano E, et al
    Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder.
    PLoS One. 2017;12:e0184012.
    PubMed     Text format     Abstract available


  47. PARK HY, Park JW, Song HJ, Sohn HS, et al
    The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea.
    PLoS One. 2017;12:e0169463.
    PubMed     Text format     Abstract available


  48. TALMAGE GD, Coppes OJM, Javed A, Bernard J, et al
    Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study.
    PLoS One. 2017;12:e0173299.
    PubMed     Text format     Abstract available


  49. ZAPRUTKO T, Kopciuch D, Kus K, Merks P, et al
    Affordability of medicines in the European Union.
    PLoS One. 2017;12:e0172753.
    PubMed     Text format     Abstract available


  50. PAUZUOLIS M, Eich T, Burman J
    Quantification of gammadelta T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.
    PLoS One. 2017;12:e0179095.
    PubMed     Text format     Abstract available


  51. CHAMI M, Halmer R, Schnoeder L, Anne Becker K, et al
    Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination.
    PLoS One. 2017;12:e0178622.
    PubMed     Text format     Abstract available


  52. ALSOP J, Medin J, Cornelissen C, Vormfelde SV, et al
    Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.
    PLoS One. 2017;12:e0173353.
    PubMed     Text format     Abstract available


  53. TAKAYASU L, Suda W, Watanabe E, Fukuda S, et al
    A 3-dimensional mathematical model of microbial proliferation that generates the characteristic cumulative relative abundance distributions in gut microbiomes.
    PLoS One. 2017;12:e0180863.
    PubMed     Text format     Abstract available


  54. JONAS SF, Mbogning C, Hassler S, Broet P, et al
    A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunology.
    PLoS One. 2017;12:e0179896.
    PubMed     Text format     Abstract available


  55. KIDD T, Carey N, Mold F, Westwood S, et al
    A systematic review of the effectiveness of self-management interventions in people with multiple sclerosis at improving depression, anxiety and quality of life.
    PLoS One. 2017;12:e0185931.
    PubMed     Text format     Abstract available


  56. FERNANDEZ O, Duran E, Ayuso T, Hernandez L, et al
    Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
    PLoS One. 2017;12:e0185766.
    PubMed     Text format     Abstract available


  57. FAVARETTO A, Lazzarotto A, Riccardi A, Pravato S, et al
    Enlarged Virchow Robin spaces associate with cognitive decline in multiple sclerosis.
    PLoS One. 2017;12:e0185626.
    PubMed     Text format     Abstract available


  58. BESELER C, Vollmer T, Graner M, Yu X, et al
    The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution.
    PLoS One. 2017;12:e0186842.
    PubMed     Text format     Abstract available


  59. RAKNES G, Smabrekke L
    Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study.
    PLoS One. 2017;12:e0187423.
    PubMed     Text format     Abstract available


  60. WYBRECHT D, Reuter F, Pariollaud F, Zaaraoui W, et al
    New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study.
    PLoS One. 2017;12:e0184650.
    PubMed     Text format     Abstract available


  61. LIU S, Liu X, Chen S, Xiao Y, et al
    Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
    PLoS One. 2017;12:e0188644.
    PubMed     Text format     Abstract available


  62. MOISSET X, Perie M, Pereira B, Dumont E, et al
    Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.
    PLoS One. 2017;12:e0188120.
    PubMed     Text format     Abstract available


    January 2016
  63. AKBAR N, Giorgio A, Till C, Sled JG, et al
    Alterations in Functional and Structural Connectivity in Pediatric-Onset Multiple Sclerosis.
    PLoS One. 2016;11:e0145906.
    PubMed     Text format     Abstract available


  64. ZHOU F, Zhuang Y, Gong H, Zhan J, et al
    Resting State Brain Entropy Alterations in Relapsing Remitting Multiple Sclerosis.
    PLoS One. 2016;11:e0146080.
    PubMed     Text format     Abstract available


  65. KIISKI HS, Ni Riada S, Lalor EC, Goncalves NR, et al
    Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis.
    PLoS One. 2016;11:e0146084.
    PubMed     Text format     Abstract available


  66. NIELSEN CH, Bornsen L, Sellebjerg F, Brimnes MK, et al
    Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-alpha and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis.
    PLoS One. 2016;11:e0146971.
    PubMed     Text format     Abstract available


  67. POPESCU V, Schoonheim MM, Versteeg A, Chaturvedi N, et al
    Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method.
    PLoS One. 2016;11:e0143942.
    PubMed     Text format     Abstract available


  68. SHINTO L, Marracci G, Mohr DC, Bumgarner L, et al
    Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study.
    PLoS One. 2016;11:e0147195.
    PubMed     Text format     Abstract available


  69. RODIC SZ, Knezevic TI, Kisic-Tepavcevic DB, Dackovic JR, et al
    Validation of the Serbian Version of Multiple Sclerosis Spasticity Scale 88 (MSSS-88).
    PLoS One. 2016;11:e0147042.
    PubMed     Text format     Abstract available


  70. RASCHE L, Heiserich L, Behrens JR, Lenz K, et al
    Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study.
    PLoS One. 2016;11:e0147968.
    PubMed     Text format     Abstract available


  71. MARCK CH, Neate SL, Taylor KL, Weiland TJ, et al
    Prevalence of Comorbidities, Overweight and Obesity in an International Sample of People with Multiple Sclerosis and Associations with Modifiable Lifestyle Factors.
    PLoS One. 2016;11:e0148573.
    PubMed     Text format     Abstract available


  72. TSCHOCHNER M, Leary S, Cooper D, Strautins K, et al
    Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis.
    PLoS One. 2016;11:e0147567.
    PubMed     Text format     Abstract available


  73. MOTTA C, Palermo E, Studer V, Germanotta M, et al
    Disability and Fatigue Can Be Objectively Measured in Multiple Sclerosis.
    PLoS One. 2016;11:e0148997.
    PubMed     Text format     Abstract available


  74. AN H, Lim C, Guillemin GJ, Vollmer-Conna U, et al
    Serum Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) Is Increased in Patients with Multiple Sclerosis and Is a Strong Independent Indicator of Disease Severity; 6.7kbp LILRA3 Gene Deletion Is Not Associated with Diseases Susceptibility.
    PLoS One. 2016;11:e0149200.
    PubMed     Text format     Abstract available


  75. KLISTORNER A, Wang C, Yiannikas C, Graham SL, et al
    Progressive Injury in Chronic Multiple Sclerosis Lesions Is Gender-Specific: A DTI Study.
    PLoS One. 2016;11:e0149245.
    PubMed     Text format     Abstract available


  76. ZAINI WH, Giuliani F, Beaulieu C, Kalra S, et al
    Fatigue in Multiple Sclerosis: Assessing Pontine Involvement Using Proton MR Spectroscopic Imaging.
    PLoS One. 2016;11:e0149622.
    PubMed     Text format     Abstract available


  77. MOUZAKI A, Rodi M, Dimisianos N, Emmanuil A, et al
    Correction: Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
    PLoS One. 2016;11:e0151411.
    PubMed     Text format     Abstract available


  78. HELLWIG K, Chen LH, Stancyzk FZ, Langer-Gould AM, et al
    Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility.
    PLoS One. 2016;11:e0149094.
    PubMed     Text format     Abstract available


  79. FAIZY TD, Thaler C, Kumar D, Sedlacik J, et al
    Heterogeneity of Multiple Sclerosis Lesions in Multislice Myelin Water Imaging.
    PLoS One. 2016;11:e0151496.
    PubMed     Text format     Abstract available


  80. CHEVALIER J, Chamoux C, Hammes F, Chicoye A, et al
    Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    PLoS One. 2016;11:e0150703.
    PubMed     Text format     Abstract available


  81. BRANGER P, Parienti JJ, Sormani MP, Defer G, et al
    The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis.
    PLoS One. 2016;11:e0149685.
    PubMed     Text format     Abstract available


  82. PINTER D, Beckmann C, Koini M, Pirker E, et al
    Reproducibility of Resting State Connectivity in Patients with Stable Multiple Sclerosis.
    PLoS One. 2016;11:e0152158.
    PubMed     Text format     Abstract available


  83. DISANTO G, Benkert P, Lorscheider J, Mueller S, et al
    The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
    PLoS One. 2016;11:e0152347.
    PubMed     Text format     Abstract available


  84. KUSPINAR A, Pickard S, Mayo NE
    Developing a Valuation Function for the Preference-Based Multiple Sclerosis Index: Comparison of Standard Gamble and Rating Scale.
    PLoS One. 2016;11:e0151905.
    PubMed     Text format     Abstract available


  85. BEGGS CB, Magnano C, Belov P, Krawiecki J, et al
    Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients.
    PLoS One. 2016;11:e0153960.
    PubMed     Text format     Abstract available


  86. LAIBLE M, Jarius S, Mackensen F, Schmidt-Bacher A, et al
    Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis.
    PLoS One. 2016;11:e0155322.
    PubMed     Text format     Abstract available


  87. MASSA MG, Gisevius B, Hirschberg S, Hinz L, et al
    Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells.
    PLoS One. 2016;11:e0155274.
    PubMed     Text format     Abstract available


  88. DORONIN VB, Parkhomenko TA, Castellazzi M, Cesnik E, et al
    Comparison of Antibodies with Amylase Activity from Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis.
    PLoS One. 2016;11:e0154688.
    PubMed     Text format     Abstract available


  89. STAMILE C, Kocevar G, Cotton F, Durand-Dubief F, et al
    A Sensitive and Automatic White Matter Fiber Tracts Model for Longitudinal Analysis of Diffusion Tensor Images in Multiple Sclerosis.
    PLoS One. 2016;11:e0156405.
    PubMed     Text format     Abstract available


  90. KARAMYAN A, Dunser MW, Wiebe DJ, Pilz G, et al
    Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study.
    PLoS One. 2016;11:e0155795.
    PubMed     Text format     Abstract available


  91. MURIS AH, Smolders J, Rolf L, Klinkenberg LJ, et al
    Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.
    PLoS One. 2016;11:e0156122.
    PubMed     Text format     Abstract available


  92. PLAISTED WC, Zavala A, Hingco E, Tran H, et al
    Remyelination Is Correlated with Regulatory T Cell Induction Following Human Embryoid Body-Derived Neural Precursor Cell Transplantation in a Viral Model of Multiple Sclerosis.
    PLoS One. 2016;11:e0157620.
    PubMed     Text format     Abstract available


  93. BOUDARHAM J, Hameau S, Zory R, Hardy A, et al
    Coactivation of Lower Limb Muscles during Gait in Patients with Multiple Sclerosis.
    PLoS One. 2016;11:e0158267.
    PubMed     Text format     Abstract available


  94. SATUE M, Rodrigo MJ, Otin S, Bambo MP, et al
    Relationship between Visual Dysfunction and Retinal Changes in Patients with Multiple Sclerosis.
    PLoS One. 2016;11:e0157293.
    PubMed     Text format     Abstract available


  95. D'AMICO E, Leone C, Graziano G, Amato MP, et al
    The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.
    PLoS One. 2016;11:e0157721.
    PubMed     Text format     Abstract available


  96. BSTEH G, Ehling R, Lutterotti A, Hegen H, et al
    Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study.
    PLoS One. 2016;11:e0158978.
    PubMed     Text format     Abstract available


  97. PAOLICELLI D, Iannazzo S, Santoni L, Iaffaldano A, et al
    The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
    PLoS One. 2016;11:e0159214.
    PubMed     Text format     Abstract available


  98. KREMER D, Cui QL, Gottle P, Kuhlmann T, et al
    CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation.
    PLoS One. 2016;11:e0146503.
    PubMed     Text format     Abstract available


  99. ERNSTSSON O, Gyllensten H, Alexanderson K, Tinghog P, et al
    Cost of Illness of Multiple Sclerosis - A Systematic Review.
    PLoS One. 2016;11:e0159129.
    PubMed     Text format     Abstract available


  100. BONNIER G, Kober T, Schluep M, Du Pasquier R, et al
    A New Approach for Deep Gray Matter Analysis Using Partial-Volume Estimation.
    PLoS One. 2016;11:e0148631.
    PubMed     Text format     Abstract available


  101. WIENDL H, Butzkueven H, Kappos L, Trojano M, et al
    Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
    PLoS One. 2016;11:e0144834.
    PubMed     Text format     Abstract available


  102. RASENACK M, Rychen J, Andelova M, Naegelin Y, et al
    Efficacy and Safety of Fingolimod in an Unselected Patient Population.
    PLoS One. 2016;11:e0146190.
    PubMed     Text format     Abstract available


  103. DAVIES JL, Thompson S, Kaur-Sandhu H, Sawcer S, et al
    Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis.
    PLoS One. 2016;11:e0158327.
    PubMed     Text format     Abstract available


  104. DENNISON L, McCloy Smith E, Bradbury K, Galea I, et al
    How Do People with Multiple Sclerosis Experience Prognostic Uncertainty and Prognosis Communication? A Qualitative Study.
    PLoS One. 2016;11:e0158982.
    PubMed     Text format     Abstract available


  105. DAHL LC, Nasa Z, Chung J, Niego B, et al
    The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis.
    PLoS One. 2016;11:e0158653.
    PubMed     Text format     Abstract available


  106. GILLI F, Chen X, Pachner AR, Gimi B, et al
    High-Resolution Diffusion Tensor Spinal Cord MRI Measures as Biomarkers of Disability Progression in a Rodent Model of Progressive Multiple Sclerosis.
    PLoS One. 2016;11:e0160071.
    PubMed     Text format     Abstract available


  107. SALEHI Z, Doosti R, Beheshti M, Janzamin E, et al
    Differential Frequency of CD8+ T Cell Subsets in Multiple Sclerosis Patients with Various Clinical Patterns.
    PLoS One. 2016;11:e0159565.
    PubMed     Text format     Abstract available


  108. MARTIN JE, Raffel J, Nicholas R
    Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care.
    PLoS One. 2016;11:e0159210.
    PubMed     Text format     Abstract available


  109. IANNETTA M, Zingaropoli MA, Bellizzi A, Morreale M, et al
    Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    PLoS One. 2016;11:e0160277.
    PubMed     Text format     Abstract available


  110. HAREL A, Ceccarelli A, Farrell C, Fabian M, et al
    Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS.
    PLoS One. 2016;11:e0152180.
    PubMed     Text format     Abstract available


  111. GRACIEN RM, Jurcoane A, Wagner M, Reitz SC, et al
    The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis.
    PLoS One. 2016;11:e0161036.
    PubMed     Text format     Abstract available


  112. FERNANDEZ O, Arroyo R, Martinez-Yelamos S, Marco M, et al
    Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart(R) Device in Patients with Relapsing-Remitting Multiple Sclerosis.
    PLoS One. 2016;11:e0160313.
    PubMed     Text format     Abstract available


  113. JELINEK GA, De Livera AM, Marck CH, Brown CR, et al
    Associations of Lifestyle, Medication, and Socio-Demographic Factors with Disability in People with Multiple Sclerosis: An International Cross-Sectional Study.
    PLoS One. 2016;11:e0161701.
    PubMed     Text format     Abstract available


  114. ROSATO R, Testa S, Bertolotto A, Confalonieri P, et al
    Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory.
    PLoS One. 2016;11:e0153466.
    PubMed     Text format     Abstract available


  115. OBERT D, Helms G, Sattler MB, Jung K, et al
    Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.
    PLoS One. 2016;11:e0162583.
    PubMed     Text format     Abstract available


  116. SOLARO C, Trabucco E, Signori A, Martinelli V, et al
    Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory.
    PLoS One. 2016;11:e0160261.
    PubMed     Text format     Abstract available


  117. TSIVGOULIS G, Katsanos AH, Mavridis D, Grigoriadis N, et al
    The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.
    PLoS One. 2016;11:e0163296.
    PubMed     Text format     Abstract available


  118. MONTI MC, Guido D, Montomoli C, Sardu C, et al
    Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia.
    PLoS One. 2016;11:e0163313.
    PubMed     Text format     Abstract available


  119. JERNAS L, Wencel J, Wiak A, Bieniek M, et al
    Risk Factors for Poor Adherence to Betaferon(R) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.
    PLoS One. 2016;11:e0157950.
    PubMed     Text format     Abstract available


  120. KAUSHIK DK, Yong HY, Hahn JN, Silva C, et al
    Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid.
    PLoS One. 2016;11:e0163802.
    PubMed     Text format     Abstract available


  121. RIEMANN-LORENZ K, Eilers M, von Geldern G, Schulz KH, et al
    Dietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program.
    PLoS One. 2016;11:e0165246.
    PubMed     Text format     Abstract available


  122. KALRON A, Givon U, Frid L, Dolev M, et al
    Static Posturography and Falls According to Pyramidal, Sensory and Cerebellar Functional Systems in People with Multiple Sclerosis.
    PLoS One. 2016;11:e0164467.
    PubMed     Text format     Abstract available


  123. HAJIEBRAHIMI M, Montgomery S, Burkill S, Bahmanyar S, et al
    Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients.
    PLoS One. 2016;11:e0165027.
    PubMed     Text format     Abstract available


  124. KREMER IE, Evers SM, Jongen PJ, van der Weijden T, et al
    Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.
    PLoS One. 2016;11:e0164862.
    PubMed     Text format     Abstract available


  125. BACHELET D, Hassler S, Mbogning C, Link J, et al
    Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
    PLoS One. 2016;11:e0162752.
    PubMed     Text format     Abstract available


  126. ALROUGHANI R, Akhtar S, Ahmed S, Behbehani R, et al
    Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
    PLoS One. 2016;11:e0165846.
    PubMed     Text format     Abstract available


  127. DOBSON R, Ramagopalan S, Topping J, Smith P, et al
    A Risk Score for Predicting Multiple Sclerosis.
    PLoS One. 2016;11:e0164992.
    PubMed     Text format     Abstract available


  128. ZHANG L, Wang L, Tian P, Tian S, et al
    Identification of Genes Discriminating Multiple Sclerosis Patients from Controls by Adapting a Pathway Analysis Method.
    PLoS One. 2016;11:e0165543.
    PubMed     Text format     Abstract available


  129. MARTIN P, McGovern A, Massey J, Schoenfelder S, et al
    Identifying Causal Genes at the Multiple Sclerosis Associated Region 6q23 Using Capture Hi-C.
    PLoS One. 2016;11:e0166923.
    PubMed     Text format     Abstract available


  130. JOHNSON TW, Wu Y, Nathoo N, Rogers JA, et al
    Gray Matter Hypoxia in the Brain of the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.
    PLoS One. 2016;11:e0167196.
    PubMed     Text format     Abstract available


  131. PIVOT D, Debouverie M, Grzebyk M, Brassat D, et al
    Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.
    PLoS One. 2016;11:e0167556.
    PubMed     Text format     Abstract available


  132. PROSPERINI L, de Rossi N, Scarpazza C, Moiola L, et al
    Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
    PLoS One. 2016;11:e0168376.
    PubMed     Text format     Abstract available


  133. BLOCK VA, Pitsch E, Tahir P, Cree BA, et al
    Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
    PLoS One. 2016;11:e0154335.
    PubMed     Text format     Abstract available


    January 2015
  134. NATHOO N, Rogers JA, Yong VW, Dunn JF, et al
    Detecting deoxyhemoglobin in spinal cord vasculature of the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis using susceptibility MRI and hyperoxygenation.
    PLoS One. 2015;10:e0127033.
    PubMed     Text format     Abstract available


  135. AKKAD DA, Olischewsky A, Reiner F, Hellwig K, et al
    Combinations of susceptibility genes are associated with higher risk for multiple sclerosis and imply disease course specificity.
    PLoS One. 2015;10:e0127632.
    PubMed     Text format     Abstract available


  136. HYUN JW, Kim SH, Jeong IH, Ahn SW, et al
    Utility of the rio score and modified rio score in korean patients with multiple sclerosis.
    PLoS One. 2015;10:e0129243.
    PubMed     Text format     Abstract available


  137. FAVARETTO A, Poggiali D, Lazzarotto A, Rolma G, et al
    The Parallel Analysis of Phase Sensitive Inversion Recovery (PSIR) and Double Inversion Recovery (DIR) Images Significantly Improves the Detection of Cortical Lesions in Multiple Sclerosis (MS) since Clinical Onset.
    PLoS One. 2015;10:e0127805.
    PubMed     Text format     Abstract available


  138. TOLLEY K, Hutchinson M, You X, Wang P, et al
    A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    PLoS One. 2015;10:e0127960.
    PubMed     Text format     Abstract available


  139. TEJERA-ALHAMBRA M, Casrouge A, de Andres C, Seyfferth A, et al
    Plasma biomarkers discriminate clinical forms of multiple sclerosis.
    PLoS One. 2015;10:e0128952.
    PubMed     Text format     Abstract available


  140. DEL PICCOLO L, Pietrolongo E, Radice D, Tortorella C, et al
    Patient expression of emotions and neurologist responses in first multiple sclerosis consultations.
    PLoS One. 2015;10:e0127734.
    PubMed     Text format     Abstract available


  141. SOLTI I, Kvell K, Talaber G, Veto S, et al
    Thymic Atrophy and Apoptosis of CD4+CD8+ Thymocytes in the Cuprizone Model of Multiple Sclerosis.
    PLoS One. 2015;10:e0129217.
    PubMed     Text format     Abstract available


  142. PERGA S, Giuliano Albo A, Lis K, Minari N, et al
    Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis.
    PLoS One. 2015;10:e0129291.
    PubMed     Text format     Abstract available


  143. VAN DER HIELE K, van Gorp D, Ruimschotel R, Kamminga N, et al
    Work Participation and Executive Abilities in Patients with Relapsing-Remitting Multiple Sclerosis.
    PLoS One. 2015;10:e0129228.
    PubMed     Text format     Abstract available


  144. MALYAVANTHAM K, Weinstock-Guttman B, Suresh L, Zivadinov R, et al
    Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.
    PLoS One. 2015;10:e0129503.
    PubMed     Text format     Abstract available


  145. MANCUSO R, Hernis A, Agostini S, Rovaris M, et al
    Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis.
    PLoS One. 2015;10:e0130715.
    PubMed     Text format     Abstract available


  146. ZHUANG Y, Zhou F, Gong H
    Intrinsic Functional Plasticity of the Sensorimotor Network in Relapsing-Remitting Multiple Sclerosis: Evidence from a Centrality Analysis.
    PLoS One. 2015;10:e0130524.
    PubMed     Text format     Abstract available


  147. AL-SHAMMRI SN, Hanna MG, Chattopadhyay A, Akanji AO, et al
    Sociocultural and Demographic Risk Factors for the Development of Multiple Sclerosis in Kuwait: A Case - Control Study.
    PLoS One. 2015;10:e0132106.
    PubMed     Text format     Abstract available


  148. ALLIZOND V, Scutera S, Rossi S, Musso T, et al
    Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data.
    PLoS One. 2015;10:e0131557.
    PubMed     Text format     Abstract available


  149. LERAY E, Vukusic S, Debouverie M, Clanet M, et al
    Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.
    PLoS One. 2015;10:e0132033.
    PubMed     Text format     Abstract available


  150. BOZIN I, Ge Y, Kuchling J, Dusek P, et al
    Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.
    PLoS One. 2015;10:e0128386.
    PubMed     Text format     Abstract available


  151. LEIKFOSS IS, Keshari PK, Gustavsen MW, Bjolgerud A, et al
    Multiple Sclerosis Risk Allele in CLEC16A Acts as an Expression Quantitative Trait Locus for CLEC16A and SOCS1 in CD4+ T Cells.
    PLoS One. 2015;10:e0132957.
    PubMed     Text format     Abstract available


  152. FAN X, Jin T, Zhao S, Liu C, et al
    Circulating CCR7+ICOS+ Memory T Follicular Helper Cells in Patients with Multiple Sclerosis.
    PLoS One. 2015;10:e0134523.
    PubMed     Text format     Abstract available


  153. HANSEN K, Schussel K, Kieble M, Werning J, et al
    Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
    PLoS One. 2015;10:e0133279.
    PubMed     Text format     Abstract available


  154. SEVERIJNS D, Octavia JR, Kerkhofs L, Coninx K, et al
    Investigation of Fatigability during Repetitive Robot-Mediated Arm Training in People with Multiple Sclerosis.
    PLoS One. 2015;10:e0133729.
    PubMed     Text format     Abstract available


  155. EHLER J, Koball S, Sauer M, Mitzner S, et al
    Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.
    PLoS One. 2015;10:e0134583.
    PubMed     Text format     Abstract available


  156. CALABRESE M, Reynolds R, Magliozzi R, Castellaro M, et al
    Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients.
    PLoS One. 2015;10:e0135428.
    PubMed     Text format     Abstract available


  157. BERTOLI D, Serana F, Sottini A, Cordioli C, et al
    Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
    PLoS One. 2015;10:e0135441.
    PubMed     Text format     Abstract available


  158. NYGAARD GO, Celius EG, de Rodez Benavent SA, Sowa P, et al
    A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.
    PLoS One. 2015;10:e0135974.
    PubMed     Text format     Abstract available


  159. ORTIZ MA, Nunez C, Ordonez D, Alvarez-Cermeno JC, et al
    Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis.
    PLoS One. 2015;10:e0134414.
    PubMed     Text format     Abstract available


  160. LOPEZ-GONGORA M, Escartin A, Martinez-Horta S, Fernandez-Bobadilla R, et al
    Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis.
    PLoS One. 2015;10:e0136786.
    PubMed     Text format     Abstract available


  161. MOUZAKI A, Rodi M, Dimisianos N, Emmanuil A, et al
    Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
    PLoS One. 2015;10:e0135434.
    PubMed     Text format     Abstract available


  162. MATTHEWS L, Kolind S, Brazier A, Leite MI, et al
    Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis.
    PLoS One. 2015;10:e0137715.
    PubMed     Text format     Abstract available


  163. MIYAKE S, Kim S, Suda W, Oshima K, et al
    Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters.
    PLoS One. 2015;10:e0137429.
    PubMed     Text format     Abstract available


  164. ZIEMSSEN T, Rauer S, Stadelmann C, Henze T, et al
    Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review.
    PLoS One. 2015;10:e0138243.
    PubMed     Text format     Abstract available


  165. WENS I, Dalgas U, Vandenabeele F, Grevendonk L, et al
    High Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise Capacity, a Randomised Controlled Trial.
    PLoS One. 2015;10:e0133697.
    PubMed     Text format     Abstract available


  166. CHOI JH, Lee MJ, Jang M, Kim EJ, et al
    An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response.
    PLoS One. 2015;10:e0138592.
    PubMed     Text format     Abstract available


  167. HADJIGEORGIOU G, Dardiotis E, Tsivgoulis G, Doskas T, et al
    Correction: Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA).
    PLoS One. 2015;10:e0140308.
    PubMed     Text format     Abstract available


  168. HEESEN C, Kasper J, Fischer K, Kopke S, et al
    Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0) - Development of an Outcome Instrument for Educational Interventions.
    PLoS One. 2015;10:e0138364.
    PubMed     Text format     Abstract available


  169. BERG S, Kaschka I, Utz KS, Huhn K, et al
    Baseline magnetic resonance imaging of the optic nerve provides limited predictive information on short-term recovery after acute optic neuritis.
    PLoS One. 2015;10:e0113961.
    PubMed     Text format     Abstract available


  170. NIELSEN HH, Beck HC, Kristensen LP, Burton M, et al
    The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study.
    PLoS One. 2015;10:e0139659.
    PubMed     Text format     Abstract available



  171. Correction: An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response.
    PLoS One. 2015;10:e0141635.
    PubMed     Text format     Abstract available


  172. JONKMAN LE, Rosenthal DM, Sormani MP, Miles L, et al
    Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis.
    PLoS One. 2015;10:e0129380.
    PubMed     Text format     Abstract available


  173. SAMUVEL DJ, Saxena N, Dhindsa JS, Singh AK, et al
    AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
    PLoS One. 2015;10:e0141781.
    PubMed     Text format     Abstract available


  174. AL-TEMAIMI RA, Al-Enezi A, Al-Serri A, Al-Roughani R, et al
    The Association of Vitamin D Receptor Polymorphisms with Multiple Sclerosis in a Case-Control Study from Kuwait.
    PLoS One. 2015;10:e0142265.
    PubMed     Text format     Abstract available


  175. BESTER M, Forkert ND, Stellmann JP, Sturner K, et al
    Correction: Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients.
    PLoS One. 2015;10:e0142464.
    PubMed     Text format     Abstract available


  176. LAMARGUE HAMEL D, Deloire M, Ruet A, Charre-Morin J, et al
    Deciphering Depressive Mood in Relapsing-Remitting and Progressive Multiple Sclerosis and Its Consequence on Quality of Life.
    PLoS One. 2015;10:e0142152.
    PubMed     Text format     Abstract available


  177. ABOULENEIN-DJAMSHIDIAN F, Krssak M, Serbecic N, Rauschka H, et al
    CROP - The Clinico-Radiologico-Ophthalmological Paradox in Multiple Sclerosis: Are Patterns of Retinal and MRI Changes Heterogeneous and Thus Not Predictable?
    PLoS One. 2015;10:e0142272.
    PubMed     Text format     Abstract available


  178. MAKSHAKOV G, Nazarov V, Kochetova O, Surkova E, et al
    Diagnostic and Prognostic Value of the Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains in Clinically Isolated Syndrome with Conversion to Multiple Sclerosis.
    PLoS One. 2015;10:e0143375.
    PubMed     Text format     Abstract available


  179. KANNEL K, Alnek K, Vahter L, Gross-Paju K, et al
    Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
    PLoS One. 2015;10:e0143393.
    PubMed     Text format     Abstract available


  180. VAN NOORT JM, Bsibsi M, Nacken PJ, Verbeek R, et al
    Therapeutic Intervention in Multiple Sclerosis with Alpha B-Crystallin: A Randomized Controlled Phase IIa Trial.
    PLoS One. 2015;10:e0143366.
    PubMed     Text format     Abstract available



  181. Correction: The Association of Vitamin D Receptor Polymorphisms with Multiple Sclerosis in a Case-Control Study from Kuwait.
    PLoS One. 2015;10:e0144565.
    PubMed     Text format     Abstract available


  182. VARGA BE, Gao W, Laurik KL, Tatrai E, et al
    Investigating Tissue Optical Properties and Texture Descriptors of the Retina in Patients with Multiple Sclerosis.
    PLoS One. 2015;10:e0143711.
    PubMed     Text format     Abstract available


  183. TSIVGOULIS G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, et al
    The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    PLoS One. 2015;10:e0144538.
    PubMed     Text format     Abstract available


  184. THALER C, Faizy T, Sedlacik J, Holst B, et al
    T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.
    PLoS One. 2015;10:e0144693.
    PubMed     Text format     Abstract available


  185. KAVALIUNAS A, Wiberg M, Tinghog P, Glaser A, et al
    Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients.
    PLoS One. 2015;10:e0145435.
    PubMed     Text format     Abstract available


  186. STELLMANN JP, Sturner KH, Young KL, Siemonsen S, et al
    Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?
    PLoS One. 2015;10:e0116559.
    PubMed     Text format     Abstract available


  187. GEVAERT T, Moles Lopez X, Sagaert X, Libbrecht L, et al
    Morphometric and quantitative immunohistochemical analysis of disease-related changes in the upper (suburothelial) lamina propria of the human bladder dome.
    PLoS One. 2015;10:e0127020.
    PubMed     Text format     Abstract available


  188. RAKUSA M, Cano SJ, Porter B, Riazi A, et al
    A predictive model for corticosteroid response in individual patients with MS relapses.
    PLoS One. 2015;10:e0120829.
    PubMed     Text format     Abstract available


  189. RIBBONS KA, McElduff P, Boz C, Trojano M, et al
    Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
    PLoS One. 2015;10:e0122686.
    PubMed     Text format     Abstract available


  190. CRUZ Y, Lorea J, Mestre H, Kim-Lee JH, et al
    Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
    PLoS One. 2015;10:e0121854.
    PubMed     Text format     Abstract available


  191. MATTIOLI F, Stampatori C, Bellomi F, Scarpazza C, et al
    Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
    PLoS One. 2015;10:e0131803.
    PubMed     Text format     Abstract available


    January 2014
  192. NOURI M, Bredberg A, Westrom B, Lavasani S, et al
    Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells.
    PLoS One. 2014;9:e106335.
    PubMed     Text format     Abstract available


  193. JONES KH, Jones PA, Middleton RM, Ford DV, et al
    Physical Disability, Anxiety and Depression in People with MS: An Internet-Based Survey via the UK MS Register.
    PLoS One. 2014;9:e104604.
    PubMed     Text format     Abstract available


  194. PRESSLAUER S, Milosavljevic D, Huebl W, Parigger S, et al
    Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.
    PLoS One. 2014;9:e89945.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: